enVista Envy Hydrophobic Acrylic Intraocular Lens
Bausch + Lomb, Inc. · Decision date Oct 23, 2026
What did the FDA decide?
FDA recorded a 30-Day Notice decision, OK30, dated 2026-10-23 for P240005/S010, a supplement to Bausch & Lomb, Inc.'s enVista Envy Hydrophobic Acrylic Intraocular Lens. The listed device category is Lens, multifocal intraocular, with Ophthalmic specialty and product code MFK. The supplement type is 30-Day Notice and the recorded reason is Process Change - Manufacturer/Sterilizer/Packager/Supplier.
The recorded statement covers a lidstock change for the enVista Hydrophobic Acrylic Intraocular Lens and the enVista Envy Hydrophobic Acrylic Intraocular Lens, non-preloaded models. This describes a packaging-material change within the existing PMA rather than a new approval of the lens system. The source record includes no documents, so the specific lidstock materials, any testing performed and the basis for the OK30 decision are not available here.
Whether the change affects sterility assurance or shelf-life claims cannot be determined from the record, and no clinical or labeling conclusions are drawn.
FDA approval order statement
lidstock change for enVista Hydrophobic Acrylic Intraocular Lens & enVista Envy Hydrophobic Acrylic Intraocular Lens non-preloaded models
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Oct 23, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P240005/S010
- Regulatory pathway
- PMA supplement
- Applicant
- Bausch + Lomb, Inc.
- Product code
- MFK
- Decision code
- OK30
- Decision date
- Oct 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lens, multifocal intraocular.
- Applicant
- Bausch + Lomb, Inc.
- Product code
- MFK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240005. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240005 · Original PMA
enVista Envy hydrophobic acrylic intraocular lens (IOL), enVista Envy toric hydrophobic acrylic intraocular lens (IOL)
P240005/S007 · Related supplement
enVista Envy hydrophobic acrylic intraocular lens (IOL)
P240005/S010 received
Application receipt date recorded by FDA.
P240005/S008 · Related supplement
enVista Envy Hydrophobic Acrylic Intraocular Lens
P240005/S009 · Related supplement
enVista Envy Hydrophobic Acrylic Intraocular Lens
P240005/S010 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P240005. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240005
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Bausch + Lomb, Inc. | PMA approval | Oct 10, 2024 | FDA | |
| Bausch + Lomb, Inc. | PMA supplement | Sep 3, 2026 | FDA | |
| Bausch + Lomb, Inc. | PMA supplement | Sep 30, 2026 | FDA | |
| Bausch + Lomb, Inc. | PMA supplement | Oct 14, 2026 | FDA |
Explore the linked device profile
Other records with product code MFK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ClearView HD intraocular lens (IOL)P200020/S013 | Lenstec, Inc. | PMA supplement | Oct 23, 2026 | FDA |
TECNIS Multi-focal 3-pc, Model ZMA00P080010/S032 | Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA |
| Rayner Intraocular Lenses , Ltd. | PMA supplement | Sep 24, 2026 | FDA | |
| Lenstec, Inc. | PMA approval | Jul 22, 2022 | FDA | |
| Johnson & Johnson Surgical Vision, Inc. | PMA approval | Jan 16, 2009 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bausch + Lomb, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1400 N. Goodman St., Rochester, NY, 14609
Sources and methodology
- Original FDA record: P240005/S010
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



